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ABSTRACT  
Objective The absence of a gold standard for scleroderma renal crisis (SRC) has hindered 
our understanding of this problem. The objective of this scoping review was to identify 
the criteria used to define SRC in order to guide the development of a consensus 
definition for SRC.  
Methods We conducted a search in three databases: Medline, Embase and non-Ovid 
Pubmed. Papers were eligible for inclusion if they were full-length articles in English 
whose main topic was SRC or scleroderma renal disease. Two reviewers independently 
screened eligible papers for final study selection. Data was extracted using a customized 
form. A web-based survey of members of the Scleroderma Clinical Trials Consortium 
was used to identify unpublished definitions of SRC.  
Results We identified 415 papers that met inclusion criteria. Forty original definitions of 
SRC were identified from 36 studies, 9 reviews and 2 editorials. There was significant 
heterogeneity in definitions. As a rule, though, in addition to new-onset hypertension and 
acute kidney injury, other common items used to define SRC included hypertensive 
encephalopathy and seizures, microangiopathic hemolytic anemia and characteristic 
changes on kidney biopsy. The web-based survey identified unpublished definitions of 
SRC that were largely consistent with the results of the published literature.  
Conclusion SRC was defined in a minority of studies and criteria were heterogeneous. A 
consensus definition of SRC is urgently needed to standardize data collection on SRC 
and further our understanding of this serious problem.  
KEYWORDS 
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1. INTRODUCTION 
 
Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc), 
affecting approximately 11% of diffuse and 4% of limited cutaneous SSc subjects. [1] Its 
clinical spectrum is broad, ranging from full-blown disease presenting as new onset of 
accelerated arterial hypertension and rapidly progressive oliguric renal insufficiency, to 
more modest elevations in blood pressure and renal dysfunction, and at times 
normotensive presentations. On the other hand, non-malignant hypertension without 
uremia, urine abnormalities and/or mild uremia attributable to other factors in the absence 
of SRC are common in SSc and should not be confused with it. [2, 3] 
 
The absence of a gold standard for SRC has hindered our understanding of this problem. 
Outcomes of SRC have been reported to vary widely, but different studies have used 
different criteria to define SRC. Although a hallmark of SSc, SRC was not retained in the 
American College of Rheumatology (ACR)/European League Against Rheumatism 
(EULAR) 2013 classification criteria for SSc because, although considered in the 
development and analysis of the criteria, it did not add to sensitivity and specificity of the 
final set of items retained. [4] This speaks not only to the rarity of SRC, but possibly also 
to the difficulty in ascertaining SRC. To date, two sets of criteria for SRC have been 
proposed and partially validated. [5, 6] We wish to build on these preliminary efforts to 
develop a consensus definition for SRC and improve systematic research in this 
condition.  
 
The purpose of this paper was to undertake a scoping review to identify definitions and 
items that have been used to define SRC. A search of the published literature was 
conducted to identify papers whose main topic was SRC or scleroderma renal disease. 
This search was supplemented by a web-based survey of members of the Scleroderma 
Clinical Trials Consortium to identify unpublished definitions of SRC. The primary 
objective was to map out the range of formal definitions used to define SRC. The 
secondary objectives were to 1) examine clinical features or predictors that have been 
shown to characterize SRC, and 2) identify items that have been proposed to distinguish 
SRC from diseases that are part of its differential diagnoses. Results from this review will 
be used to guide the development of a consensus definition for SRC. 
 
2. METHODS 
 
This scoping review was conducted using the Arksey and O’Malley framework [7] and 
further guided by the methodology from recent scoping review publications [8]. The 
review included the following six key phases: 1) identifying the research question, 2) 
identifying relevant studies, 3) study selection, 4) charting the data, 5) collating, 
summarizing, and reporting the results, and 6) consultation exercise.  
 
2.1. Research question 
 
This scoping review was guided by the question, “What are the items that have been used 
to define, characterize or predict scleroderma renal crisis in the literature?”  
 2.2. Data sources and search strategy 
 
The comprehensive search was implemented on June 17, 2016, in three electronic 
databases including MEDLINE (Ovid) (1946-present), EMBASE (Ovid) (1947-present) 
and Pubmed (1966-present) by one author (SH), with the assistance of a professional 
librarian. No limits on date, language, subject or type were placed on the database search. 
The search query was constructed to capture articles that addressed the topics of renal 
insufficiency or malignant hypertension in SSc. The search query was tailored to the 
specific requirements of each database (Supplementary File 1).  
 
The reference lists of 15 pre-selected relevant review articles were manually searched to 
identify any further studies not yet captured. A “snowball” technique was also adopted in 
which citations within articles were searched if they appeared relevant to the review [8].  
 
2.3. Citation management 
 
Duplicate citations were initially removed in Ovid for citations from Medline and 
EMBASE. Citations from Ovid and Pubmed were then imported into the bibliographic 
manager EndNote X7.4 (Thomson Reuters) and duplicate citations were further removed 
manually following a 12-step method of de-duplication [9]. Citations were finally 
imported into Microsoft Excel 2010 for title and abstract relevance screening and data 
extraction of full articles. Additional duplicates were removed when found later in the 
process. 
 
2.4. Eligibility criteria 
 
A two-stage screening process was used to assess the relevance of papers identified in the 
search. Papers were eligible for inclusion if they were full-length articles in English 
language whose main topic of study was SRC or scleroderma renal disease. Articles that 
did not present human data were excluded.  
 
2.5. Title and abstract relevance screening 
 
A primary screen of the papers retrieved by the search was conducted by two reviewers 
(SH and ES) working independently. Titles and abstracts were reviewed for eligibility 
using a customized study eligibility form. Titles for which an abstract was not available 
and/or for which the screening decision was uncertain were included for subsequent 
review of the full text. Any disagreements regarding the inclusion or exclusion of an 
article were resolved by consensus. All papers not meeting the eligibility criteria were 
excluded and the reason for their exclusion were noted.  
 
2.6. Data characterization 
 
All citations deemed relevant after title and abstract screening were procured for 
subsequent review of the full-text article. Papers that could not be obtained through 
institutional holdings available to the primary author were requested through interlibrary 
loans.  
 
Data from included papers were charted by one reviewer (SH), using a pretested data 
charting form in Microsoft Excel 2010. Extracted data included: author(s), year of 
publication, publication type, main topic of the study, and data relevant to the specific 
objectives of this scoping review, i.e. 1) formal definitions of SRC used in the literature, 
2) clinical features or predictors that have been shown to characterize SRC (limiting this 
question to original studies of at least 50 SSc subjects), and 3) items that distinguish SRC 
from its differential diagnoses.  
 
2.7. Web-based survey of members of the Scleroderma Clinical Trials Consortium 
 
With the aim of identifying unpublished working definitions of SRC, a web-based survey 
was sent out in September 2016 to members of the Scleroderma Clinical Trials 
Consortium, an international consortium representing the vast majority of researchers and 
clinicians who have particular interest and expertise in the care of, and research in, 
scleroderma. Members were invited to answer the following questions:  
 
1. What criteria do you use to define SRC in research studies that you currently lead 
or have led in the past? 
2. Have you participated in clinical trials that have used formal criteria to define 
SRC? (If yes, respondents were asked to provide the criteria or the name or details 
of the study). 
3. Have you participated in observational studies that have used formal criteria to 
define SRC? (If yes, respondents were asked to provide the criteria or the name or 
details of the study). 
 
2.8. Data summary and presentation 
 
Tables and charts were produced to compile the data. Descriptive statistics were used to 
summarize the results. A list of candidate items to guide the development of a consensus 
definition for SRC was created. Results of the scoping review were presented to the 
Scleroderma Clinical Trials Consortium SRC working group at the American College of 
Rheumatology annual meeting on November 12, 2016 in Washington, D.C., USA.  
 
3. RESULTS 
 
3.1. Search results and study characteristics 
 
The search identified 4146 potentially relevant citations. Twelve additional citations were 
identified through search of reference lists and the “snowball” technique. After de-
duplication and relevance screening, 501 citations met the eligibility criteria based on 
title and abstract and 483 corresponding full-text articles were procured for review. After 
full-text review, 415 papers met the inclusion criteria. The study selection process is 
presented as a flowchart in Figure 1.  
 
General characteristics of included papers are presented in Table 1. Papers were 
published from 1952 to 2016, with the majority of studies being published in the last 2 
decades. Among these, only 81 articles reported a formal definition of SRC.  
 
3.2. Formal definitions of SRC 
 
In total, 40 original definitions of SRC were identified from 36 original studies, 9 reviews 
and 2 editorials (Supplementary Table 2). There was significant heterogeneity in 
definitions. As a rule, though, in addition to new-onset hypertension and renal 
insufficiency, other common items used to define SRC included hypertensive 
encephalopathy and seizures, microangiopathic hemolytic anemia (MAHA), 
thrombocytopenia, and characteristic changes on kidney biopsy. Kidney biopsy was 
reported to be of particular interest in the normotensive SRC subset. 
 
3.3. Clinical predictors of SRC 
 
Clinical predictors significantly associated with SRC were reported in 23 original studies 
of at least 50 subjects and included shorter disease duration, diffuse cutaneous 
involvement, high skin score, large joint contractures, anti-RNA polymerase III positivity 
and recent exposure to corticosteroids (Table 2) [10-31].  
 3.4. Differential diagnoses of SRC 
 
Seventy-five (75) studies addressed differential diagnoses of SRC, the most common of 
which were anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis 
(37%) and thrombotic thrombocytopenic purpura (TTP) / hemolytic uremic syndrome 
(HUS) (21%). Other differential diagnoses reported included membranous (7%) and 
membranoproliferative (1%) nephropathies, other vasculitides (including polyarteritis 
nodosa, mixed cryoglobulinemia and Goodpasture syndrome) (7%), drug-induced 
nephropathies (due to D-penicillamine or cyclosporin A) (5%), oxalate nephropathy 
(4%), renal artery stenosis (4%) and pre-renal causes (e.g. sepsis, dehydration) (1%).  
 
In ANCA-associated glomerulonephritis, presence of ANCA (especially MPO-ANCA, 
observed in >95%), pauci-immune necrotizing and crescentic glomerulonephritis on 
kidney biopsy, presence of other vasculitic manifestations (such as pulmonary 
hemorrhage, vasculitic skin rash and limb ischemia), and treatment response to 
immunosuppressive therapy were described as items that could distinguish this entity 
from SRC [32, 33]. In addition, ANCA-associated glomerulonephritis is reported in 
patients from all SSc subsets (including limited and sine scleroderma in 59%), with anti-
Scl70 antibodies (77%) and with longer disease duration of SSc compared to SRC (8±7.7 
years vs. 7.5 months) [32, 33]. ANCA-associated glomerulonephritis patients also 
differed by their clinical presentation, being more frequently normotensive or with mildly 
elevated systolic blood pressure (below 160 mmHg) (82%), and rarely had MAHA, 
thrombocytopenia or hyper-reninemia [33, 34]. 
 
In regards to TTP, deficiency of ADAMTS-13 activity with presence of anti-ADAMTS-
13 autoantibodies, severe thrombocytopenia (especially <50,000/µl), hemorrhagic 
complications (such as purpura and gastrointestinal bleeding), fever and dramatic 
response to plasmapheresis were highlighted as items supporting a diagnosis of TTP 
rather than SRC [35, 36]. Such patients were also often normotensive and with limited 
SSc of long disease duration [37]. On kidney biopsy, studies reported the predominance 
of primary glomerular capillary microangiopathic changes in TTP-HUS, whereas in SRC, 
extra-glomerular small vessel lesions predominated [38].  
 
Oxalate nephropathy should be suspected in SSc patients with severe gastrointestinal 
involvement leading to fat malabsorption or small intestinal bacterial overgrowth and 
need for antibiotics. Such patients are often normotensive, with no signs of hemolysis and 
an inactive urine sediment. Oxalate crystals on urinalysis, increased oxalate on 24-hour 
urine collection, and biopsy demonstrating diffuse intra-tubular deposits of calcium-
containing birefringent crystals all point towards this diagnosis [39-41].  
 
Renal artery stenosis should be suspected if there is significant and persistent worsening 
of renal function on ACE inhibitor therapy. Imaging of the renal arteries can confirm the 
diagnosis. This entity has been increasingly observed in elderly subjects, particularly 
those with diabetes mellitus [42].  
 Finally, for other differential diagnoses, suspicion was mostly based on compatible 
clinical context (e.g. for drug-induced nephropathies or pre-renal causes), laboratory 
findings (e.g. for mixed cryoglobulinemia and Goodpasture syndrome) and kidney biopsy 
results (e.g. for membranous and membranoproliferative nephropathies), particularly in 
patients with inadequate response to ACE inhibitors.   
 
3.5. Web-based survey of members of the Scleroderma Clinical Trials Consortium 
 
Twenty-eight (28/155, 18%) members of the Scleroderma Clinical Trials Consortium 
responded to the survey. Most (96%) were rheumatologists and one respondent was a 
nephrologist/internist. Respondents were mostly from North America (64%) and Europe 
(25%). Overall, 60% of respondents had led research studies requiring a definition for 
SRC. Among these, 35% defined SRC according to the treating physician, while 65% 
used preexisting definitions. In addition, 21% and 46% had participated in clinical trials 
and observational studies that had used formal criteria to define SRC.  
 
Overall, this exercise identified unpublished definitions of SRC that were largely 
consistent with the results of the published literature. In addition, novel concepts included 
the stratification of SRC into definite SRC (defined as at least two of: new onset systemic 
hypertension, MAHA and rising creatinine) and suspected SRC (defined as new onset 
hypertension); the distinction between classic SRC and subacute forms of SRC (such as 
hypertension, renal insufficiency and renal sediment changes in the absence of MAHA); 
the addition of ACE inhibitor responsiveness as a characteristic of hypertension (in 
probable SRC); and the addition of more specific time frames for measurement of blood 
pressure (taken twice, 2 hours apart, within 3 days of first event-associated observation). 
 
* CAT-192 trial: Dr. Denton, could you provide us with study definition? 
 
4. DISCUSSION 
 
We conducted a rigorous scoping review of the literature to identify variables that were 
used to define, characterize or predict SRC. Definitions were heterogeneous and reported 
in a minority of studies. Several patient-specific, SSc-specific and SRC-specific variables 
predicted the presence or risk of developing SRC in SSc; however, included studies were 
of variable methodologic quality, with a number of limitations, including small, selected 
samples, retrospective designs, and paucity of controlled data or multivariate analyses. 
Nonetheless, we used this evidence base to generate a comprehensive list of potential 
candidate items that could be used to develop a definition for SRC (Table 3).  
 
Given that we limited our search of the published literature to full-text articles published 
in English and whose main topic was SRC or scleroderma renal disease, it is possible that 
we missed some published definitions of SRC in other languages or in papers where SRC 
was a secondary interest. In particular, randomized controlled trials of therapies in SSc 
were not well captured in our scoping review, given that such studies most often did not 
look at SRC as a primary outcome. Furthermore, most experimental trials have 
definitions of SRC in their protocol manuals, but these definitions are often not 
published. On the other hand, our search of the unpublished literature through a web-
based survey of members of the Scleroderma Clinical Trials Consortium uncovered 
several definitions, in particular from randomized clinical trials. Moreover, these were 
consistent with the published literature and support the fact that our comprehensive 
review strategy most likely captured all of the relevant items used to define SRC.  
 
In conclusion, criteria used to define SRC are used in a minority of studies and are highly 
heterogeneous. There is an increasing number of clinical trials in SSc being planned, 
many of which are in early diffuse disease. These represent unique opportunities to 
identify and study SRC. However, this will only be possible if investigators use a 
common definition of SRC. Hence, a consensus definition of SRC is urgently needed to 
standardize data collection on SRC. This scoping review will be used as a starting point 
to guide the development of a consensus definition for SRC.  
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